The global research antibodies market size
is expected to reach USD 4.30 billion by 2025, according to a new report by
Grand View Research, Inc., expanding at a CAGR of 6.1% during the forecast
period. The market is predominantly driven by growing number of R&D
collaborations among various public and private organizations to promote
technical advancements in product development activities and disease progression
studies. Consistent recommendations and guidelines issued by regulatory
organizations for laboratories to facilitate generation of accurate results and
ensure high-quality standards are slated to enhance adoption of research
antibodies over the coming years. For instance, in May 2016, the International
Society for Stem Cell Research issued revised guidelines for cell-based
therapies. The revised guidelines were issued with a focus to improve overall
efficiency and quality of preclinical studies.
In addition, prominent market players are
entering into partnership with R&D entities that are anticipated to open
new avenues. In December 2016, Bayer AG and Versant Ventures collaborated to
invest around USD 225.0 million for the establishment of a stem cell research
facility in Canada to encourage commercialization of regenerative medicine
therapies. Increasing prevalence of breast cancer and soaring need for
personalized medicine is stirring up the demand for advanced techniques, which
in turn is creating ample growth opportunities for the research antibodies
market.
Full research report on research antibodies market analysis: https://https://www.grandviewresearch.com/industry-analysis/research-antibodies-market
Further key findings from the report suggest:
·
Primary antibodies were the most prominent
product segment in 2016 owing to greater specificity leading to increased
adoption in research activities. The segment is expected to account for more
than 65.0% of the overall market revenue by 2025
·
On the basis of type, monoclonal antibodies
captured substantial share of the market in 2016, owing to high sensitivity for
detection of antigens and efficient staining properties with less background
noise. The segment is anticipated to rise at a CAGR of 6.6% during the forecast
period
·
Western blotting commanded the leading
share in the market, due to benefits such as better immunogenic response from
infectious agents and higher cost efficiency. The immunoprecipitation segment
is estimated to post the highest CAGR of just over 7.0% during the same period
·
Mouse antibodies are relatively easier to
produce and possess greater specificity, thus resulting in higher adoption in
R&D and accounting for the largest market share in 2016.
·
Oncology accounted for over 36.0% of the
overall revenue in 2016 as a consequence of growing cancer population
·
Pharmaceutical & biotechnology
companies will be the leading end users of research antibodies owing to
increased adoption in drug development and discovery. The segment is poised to
represent more than 61.0% of the overall revenue by 2025.
·
Contract research organizations are likely
to be the most promising end-user segment during the forecast period owing to
greater cost efficiency
·
North America will continue to be the
dominant revenue contributor throughout the forecast period owing to local
presence of various biotechnology & biopharmaceutical manufacturers
striving to compete in the market
·
Some of the key players in the global arena
are Abcam PLC; Agilent Technologies; and Thermo Fisher Scientific, Inc. The
research antibodies market is moderately consolidated and highly competitive
due to low entry barriers.
View more reports of this category by Grand View Research
at: https://www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented the
global research antibodies market on the basis of product, type, technology,
source, application, end-use, and region:
Research Antibodies Product Outlook (Revenue, USD
Million, 2014 - 2025)
·
Primary
·
Secondary
Research Antibodies Type Outlook (Revenue, USD Million,
2014 - 2025)
·
Monoclonal Antibodies
·
Polyclonal Antibodies
Research Antibodies Technology Outlook (Revenue, USD
Million, 2014 - 2025)
·
Immunohistochemistry
·
Immunofluorescence
·
Western Blotting
·
Flow Cytometry
·
Immunoprecipitation
·
ELISA
·
Others
Research Antibodies Source Outlook (Revenue, USD Million,
2014 - 2025)
·
Mouse
·
Rabbit
·
Goat
·
Others
Research Antibodies Application Outlook (Revenue, USD
Million, 2014 - 2025)
·
Infectious Diseases
·
Immunology
·
Oncology
·
Stem Cells
·
Neurobiology
·
Others
Research Antibodies End-use Outlook (Revenue, USD
Million, 2014 - 2025)
·
Academic & Research Institutes
·
Contract Research Organizations
·
Pharmaceutical & Biotechnology
Companies
Research Antibodies Regional Outlook (Revenue, USD
Million, 2014 - 2025)
·
North America
o U.S.
o Canada
·
Europe
o U.K.
o Germany
·
Asia Pacific
o Japan
o China
o India
·
Latin America
o Brazil
o Mexico
·
Middle East & Africa
o South Africa
Access Full Press Release of this
Report: https://www.grandviewresearch.com/press-release/global-research-antibodies-market
About Grand View Research
Grand View
Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more information: https://www.grandviewresearch.com/
